Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
source: shutterstock.com

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

Carisma Therapeutics, the manufacturer of CT-0508, issued a press release stating that researchers are conducting a combination study using CAR-M cell therapy plus Keytruda (pembrolizumab) in the treatment of overexpressing…

Continue Reading Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
Vyjuvek for DEB Earns Orphan Drug Designation in Japan
source: pixabay.com

Vyjuvek for DEB Earns Orphan Drug Designation in Japan

Healio Psoriatic Disease recently reported that Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy designed for people with dystrophic epidermolysis bullosa (DEB), was granted Orphan Drug designation (ODD) by the Japanese…

Continue Reading Vyjuvek for DEB Earns Orphan Drug Designation in Japan
Alzheimer’s: A Neuroscientist at the OHSU Claims Scientists Missed a Major Form of Cell Death
source: pixabay.com

Alzheimer’s: A Neuroscientist at the OHSU Claims Scientists Missed a Major Form of Cell Death

Ferroptosis, a form of cell death, destroys microglia cells, which are associated with the brain’s immune system in vascular dementia and Alzheimer’s. Dr. Stephen Back suggested that attention had not…

Continue Reading Alzheimer’s: A Neuroscientist at the OHSU Claims Scientists Missed a Major Form of Cell Death